Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.76 |
| ▸ | JAK3 | P52333 | 3/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 15/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338305 | 0.93 | NTRK1 (0.78) | JAK2JAK3NTRK1IGF1R | |
| SCHEMBL2490059 | 0.86 | JAK2 (1.00) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL14840573 | 0.86 | JAK2 (1.00) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2490060 | 0.86 | JAK2 (1.00) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL22535688 | 0.81 | NTRK1 (0.76) | JAK2JAK3NTRK1IGF1R | |
| SCHEMBL2634279 | 0.81 | NTRK1 (0.82) | JAK2JAK3NTRK1IGF1R | |
| SCHEMBL22535319 | 0.81 | JAK2 (0.71) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL4144686 | 0.81 | NTRK1 (1.00) | NTRK1IGF1R | |
| SCHEMBL4160441 | 0.81 | NTRK1 (0.82) | JAK2JAK3NTRK1IGF1R | |
| SCHEMBL4694139 | 0.81 | NTRK1 (0.82) | JAK2JAK3NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | ASTRAZENECA (SE) | 2008-08-14 | — | — | US | claimed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885NTRK1 4690/4885 |
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | TYMS, TYMP, DPYD | JAK2 455/4885JAK3 356/4885NTRK1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.